AREC.L Stock Analysis
AR
Uncovered
Arecor Therapeutics PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Arecor Therapeutics Plc is a biopharmaceutical company that targets improving patient care by bringing medicines to market through the enhancement of existing therapeutic products. The company is headquartered in Saffron Walden, Essex and currently employs 37 full-time employees. The company went IPO on 2021-06-03. The firm targets improving patient care by bringing medicines to market through the existing therapeutic products. The Company’s insulin products include NovoRapid and Fiasp. The Company’s formulation technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat platform is supported by a range of patent portfolio. The Company’s lead product, AT247, is an Arestat enabled novel formulation of insulin designed to accelerate the absorption of insulin post injection, to enable more effective management of blood glucose levels for people living with diabetes.